BOSTON, MA--(Marketwire - November 10, 2007) - Targeted Genetics Corporation (NASDAQ: TGEN) today announced that interim data from its Phase I/II trial of tgAAC94 for inflammatory arthritis suggest that the investigational therapy showed improvement in patient reported outcome measures.
